secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
CIK:        0001137883
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001104659-23-090892
Event type: earnings
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BrainStorm Q2 net loss $5.3M; NurOwn ADCOM set for Sep 27, PDUFA Dec 8
----------------------------------------------------------------------

- Net loss of $5.3M ($0.13 per share) vs $7.0M in Q2 2022.
- Cash $0.75M at June 30; raised $7.5M in July direct offering.
- FDA ADCOM for NurOwn BLA scheduled Sep 27; PDUFA target Dec 8, 2023.
- Appointed Dr. Bob Dagher as Chief Development Officer and Dr. Kirk Taylor as Chief Medical Officer.
- Biomarker data from Phase 3 showed NurOwn lowered neurofilament light, a predictor of clinical benefit in ALS.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1137883/000110465923090892/0001104659-23-090892-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1137883/000110465923090892/tm2323640d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-090892

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer